Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wiki-How: FDLI Panel Cautions Firms On New Media Use

Executive Summary

YouTube contests for promotional consumer videos may elicit laughs for many products but probably not for prescription drugs, both FDA and industry experts caution drug companies

You may also be interested in...



New Media Is The New Frontier For Drug Promotion

Pharma needs to take hold of new media and start closely monitoring consumer behavior to survive in a changing advertising climate, panelists said at a recent DTC conference

New Media Is The New Frontier For Drug Promotion

Pharma needs to take hold of new media and start closely monitoring consumer behavior to survive in a changing advertising climate, panelists said at a recent DTC conference

FDA’s Advertising Enforcement Turns Its Focus To YouTube, ADHD Drugs

FDA's spate of five promotional citations to manufacturers of attention deficit/hyperactivity disorder drugs signals that the agency intends to remain vigilant in oversight of new media

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel